![Sample our Engineering & Technology journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5933/TOC-Subject-Sample-2021-Engineering-Tech.jpg"})
Abstract
Aims: Antibody-labeled gold nanoparticles represent an attractive tool for cancer imaging and therapy. In this study, the anti-CD105 antibody was conjugated with gold nanoparticles (AuNPs) for the first time. The antibody biodistribution in mice before and after conjugation to AuNPs was studied, with a focus on tumor targeting. Materials & methods: Antibodies were radiolabeled with 89Zr before conjugation to AuNPs (5 nm). Immunonanoconjugates were characterized in vitro in terms of size, stability in plasma and binding to the target. Quantitative PET imaging and ICP-MS analysis assessed in vivo distribution and specific tumor targeting of tracers. Results: The tumor uptake of immunoconjugates was preserved up to 24 h after injection, with high tumor contrast and selective tumor targeting. No major tracer accumulation was observed over time in nonspecific organs. ICP-MS analysis confirmed the antibody specificity after nanoparticle conjugation. Conclusion: The anti-CD105 antibody conjugation to AuNPs did not greatly affect CD105-dependent tumor uptake and the efficacy of tumor targeting for cancer detection.
Supplementary Material
Financial & competing interests disclosure
This work was supported by grants from the Walloon Region through the ‘TARGAN’ project, and from the Belgian National Fund for Scientific Research (FNRS-TELEVIE). The hybridoma (clone MJ7/18) was obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology (IA, USA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.
Additional information
Funding
Notes on contributors
Linda Karmani
Biomedical Magnetic Resonance Group (REMA), Louvain Drug Research Institute, Université Catholique de Louvain, Avenue Mounier 73, 1200 Brussels, Belgium
Virginie Bouchat
Research Centre for the Physics of Matter and Radiation (PMR-LARN), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Rue de Bruxelles 61, 5000 Namur, Belgium
Caroline Bouzin
Pharmacology and Therapeutics Unit (FATH), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain, Avenue Mounier 53, 1200 Brussels, Belgium
Philippe Levêque
Biomedical Magnetic Resonance Group (REMA), Louvain Drug Research Institute, Université Catholique de Louvain, Avenue Mounier 73, 1200 Brussels, Belgium
Daniel Labar
Centre for Molecular Imaging, Radiotherapy and Oncology (MIRO), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain, Avenue Hippocrate 54, 1200 Brussels, Belgium
Anne Bol
Centre for Molecular Imaging, Radiotherapy and Oncology (MIRO), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain, Avenue Hippocrate 54, 1200 Brussels, Belgium
Gladys Deumer
Laboratory of Analytical Biochemistry and Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Avenue Hippocrate 10, 1200 Brussels, Belgium
Riccardo Marega
Department of Chemistry and Namur Research College (NARC), University of Namur, Rue de Bruxelles 61, 5000 Namur, Belgium
Davide Bonifazi
Department of Chemistry and Namur Research College (NARC), University of Namur, Rue de Bruxelles 61, 5000 Namur, Belgium
Vincent Haufroid
Laboratory of Analytical Biochemistry and Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Avenue Hippocrate 10, 1200 Brussels, Belgium
Carine Michiels
Unité de Recherche en Biologie Cellulaire (URBC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Rue de Bruxelles 61, 5000 Namur, Belgium
Vincent Grégoire
Centre for Molecular Imaging, Radiotherapy and Oncology (MIRO), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain, Avenue Hippocrate 54, 1200 Brussels, Belgium
Olivier Feron
Pharmacology and Therapeutics Unit (FATH), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain, Avenue Mounier 53, 1200 Brussels, Belgium
Stéphane Lucas
Research Centre for the Physics of Matter and Radiation (PMR-LARN), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Rue de Bruxelles 61, 5000 Namur, Belgium
Thierry Vander Borght
Centre for Molecular Imaging, Radiotherapy and Oncology (MIRO), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain, Avenue Hippocrate 54, 1200 Brussels, Belgium
Bernard Gallez
Biomedical Magnetic Resonance Group (REMA), Louvain Drug Research Institute, Université Catholique de Louvain, Avenue Mounier 73, 1200 Brussels, Belgium.